Search papers, labs, and topics across Lattice.
This commentary discusses the potential of artificial intelligence (AI) and computational biology to improve ovarian cancer diagnosis and treatment. It highlights key areas where AI and computational tools can be leveraged, including pathology, tumor biology, and precision medicine for rare subtypes of ovarian cancer. The commentary also addresses the limitations and risks associated with the application of these technologies.
AI and computational biology hold promise for improving outcomes in ovarian cancer by addressing challenges in diagnosis, treatment, and precision medicine.
Artificial intelligence and computational biology are rapidly advancing, offering unprecedented opportunities to transform both ovarian cancer research and clinical care. However, limited understanding of how to optimally integrate the information these tools provide with existing clinical data has led to a lag in integration. This commentary emerges from a unique and focused ovarian cancer research conference that explored how these emerging tools and technologies ( i.e. , artificial intelligence and computational biology) can be leveraged to address questions in pathology, develop new paradigms of tumor biology, and integrate precision medicine into clinical management of complex and rare subtypes of ovarian cancer. We highlight key ways in which systematic integration of Artificial intelligence (AI) and computational tools can be leveraged to improve outcomes in ovarian cancer as well as the limitations and risks of their application.
